

From: [Witkowski, Terry \[IBPE\]](#)
To: [Robert Fecik](#)
Cc: [Jorgenson, Debbie \[IBPE\]](#); [Funk, Andrew \[IBPE\]](#)
Subject: RE: Reactivating a Lapsed License
Date: Thursday, December 03, 2015 10:07:01 AM

Robert,

You should provide any records of pharmacist continuing education that you have completed since your Iowa license lapsed in 2000. Also, if you have any other activities or accomplishments relative to the practice of pharmacy or your continued competency to practice pharmacy those activities or accomplishments should be identified to the Board.

If you want to provide that information in advance of the Board meeting, those materials need to be delivered to Debbie Jorgenson at debbie.jorgenson@iowa.gov or mailed to Debbie's attention at 400 SW 8th Street, Suite E, Des Moines, IA 50309-4688, so the materials are received in our office no later than December 29, 2015.

If you want to distribute anything in hard-copy at the meeting, please bring 20 copies of that material.

If you have any questions regarding your appearance, please contact Debbie. The meeting tentative timetable will be established and available on the Board's website after December 29, 2015. If you need a more definite time in order to accommodate your travel, please contact Debbie and she will try to work with your schedule.

Thank you.

Therese (Terry) Witkowski
Executive Officer
Iowa Board of Pharmacy
terry.witkowski@iowa.gov
515-281-6676

The Iowa Board of Pharmacy promotes, preserves, and protects the public health, safety, and welfare through the effective regulation of the practice of pharmacy and the licensing of pharmacies, pharmacists, and others engaged in the sale, delivery, or distribution of prescription drugs and devices. Iowa Code § 155A.2(1).

-----Original Message-----

From: Robert Fecik [<mailto:fecik001@umn.edu>]
Sent: Thursday, December 03, 2015 9:25 AM
To: Witkowski, Terry [IBPE]
Subject: Re: Reactivating a Lapsed License

Dear Terry,

Thank you for your advice and assistance. I will plan to attend the Board meeting on January 13. Are there any documents or information the Board would like to have in advance of the meeting?

Best,

Robert

Robert A. Fecik
Associate Professor
Department of Medicinal Chemistry

University of Minnesota
308 Harvard St. S.E., 8-121 WDH
Minneapolis, MN 55455
Tel: 612-625-9335
FAX: 612-626-6318
fecik001@umn.edu

> On Dec 3, 2015, at 7:32 AM, Witkowski, Terry [IBPE] <Terry.Witkowski@iowa.gov> wrote:

>

> Robert,

>

> Your recollection of our previous discussions is correct. I am forwarding your email to Debbie to add to the January Board meeting agenda. The January meeting is scheduled for January 13, 2016, at the Board office in Des Moines.

>

> Debbie, please add this request to the Board meeting agenda and provide time for Mr. Fecik to present his request to the Board.

>

> Thank you.

>

> Therese (Terry) Witkowski

> Executive Officer

> Iowa Board of Pharmacy

> terry.witkowski@iowa.gov

> 515-281-6676

>

> The Iowa Board of Pharmacy promotes, preserves, and protects the public health, safety, and welfare through the effective regulation of the practice of pharmacy and the licensing of pharmacies, pharmacists, and others engaged in the sale, delivery, or distribution of prescription drugs and devices. Iowa Code § 155A.2(1).

>

>

>

> -----Original Message-----

> From: Robert Fecik [<mailto:fecik001@umn.edu>]

> Sent: Wednesday, December 02, 2015 4:53 PM

> To: Witkowski, Terry [IBPE]

> Subject: Reactivating a Lapsed License

>

> Dear Terry:

>

> I had written to you previously about 1–2 years ago, and unfortunately I do not have an archive of our previous communication regarding reactivation of my lapsed license. My license number is 18381, and I was last licensed for the July 1, 1998 to June 30, 2000 period.

>

> To the best of my recollection, your response to my previous inquiry was that since my license had lapsed for greater than ten years reinstatement would entail: (1) Completion of current and past due CEs, (2) payment of any applicable past due fees and a fine, (3) potentially completion of an unspecified number of intern hours, and (4) potentially meeting with the Board.

>

> I would like to proceed with completing any Board requirements for reactivation of my license. To confirm exactly what this would entail, I am requesting a meeting with the Board at their earliest convenience in 2016.

> Despite the inactive state of my license I have been active in the profession as a faculty member at the University of

Minnesota College of Pharmacy since 2001. I would welcome a discussion with the Board to determine the most appropriate path forward for reactivation of my license.

>

> I'm grateful to both you and the Board for the consideration of my case. Please do not hesitate to contact me at your convenience if you have any further questions at this time, or if there is additional information I can provide to you.

>

> Sincerely,

>

> Robert

>

> Robert A. Fecik

> Associate Professor

> Department of Medicinal Chemistry

> University of Minnesota

> 308 Harvard St. S.E., 8-121 WDH

> Minneapolis, MN 55455

> Tel: 612-625-9335

> FAX: 612-626-6318

> fecik001@umn.edu

>

>

>

>

>

>

>

>

> This email message and its attachments may contain confidential information that is exempt from disclosure under Iowa Code chapters 22, 139A, and other applicable law. Confidential information is for the sole use of the intended recipient. If you believe that you have received this transmission in error, please reply to the sender, and then delete all copies of this message and any attachments. If you are not the intended recipient, you are hereby notified that any review, use, retention, dissemination, distribution, or copying of this message is strictly prohibited by law.

UNIVERSITY OF MINNESOTA

Twin Cities Campus

*Department of Medicinal Chemistry
College of Pharmacy*

*308 Harvard Street S.E.
Room 8-121
Minneapolis, MN 55455*

*Robert A. Fecik
Associate Professor*

*Tel: 612-625-9335
E-mail: fecik001@umn.edu*

Iowa Board of Pharmacy
c/o Debbie Jorgenson
400 SW 8th Street, Suite E
Des Moines, IA 50309-4688

December 28, 2015

Dear Board Members:

The enclosed materials are for your consideration of my pending request to reactivate my Iowa pharmacy license #18381. The last renewal period for my license was the July 1, 1998 to June 30, 2000 period. I will be at the January 13, 2016 meeting to discuss the specific requirements for license reactivation with you. Included here is my CV, and certificates of completion for CEs earned since my license lapsed in 2000. These CEs were completed in January 2004 (6.6 CEUs), including 6.0 CEUs in drug therapy-related topics, 0.4 CEUs in general pharmacy topics, and 0.2 CEUs in pharmacy law topics. It is my hope that these CE credits can be used in partial fulfillment of my CE requirement for license reactivation.

Although my license has remained inactive for 15 years, I have been continuously and actively involved in the profession in my capacities as a faculty member of the University of Minnesota College of Pharmacy since my appointment in 2001 to the Department of Medicinal Chemistry. During this time, I have taught approximately 30 in-class hours per year in Pharm.D. curriculum. Although the specific course assignments for me have changed over the years, I have consistently taught in the medicinal chemistry courses focused on medicinal agents. This has included major topics such as cardiovascular drugs, CNS drugs, and anti-cancer agents. The integrated nature of the Pharm.D. curriculum at Minnesota requires communication with therapy- and practice-focused faculty in teaching my basic science content. This has enabled me to keep abreast of new and changing practice standards.

Additionally, my research activities at Minnesota have largely focused on the discovery of novel macrolide antibiotics and tubulin-binding anticancer agents. Success in these research areas has required me to pay keen attention to new developments in these therapeutic areas. My research activities have culminated in discovery of analogs of tubulysin natural products for the treatment of drug-resistant cancers. We have patented this invention, and the University of Minnesota and I are currently in discussion with numerous biotech and pharmaceutical companies to license the intellectual property with the intent to prepare an antibody-drug conjugate for clinical trials.

Other professional activities of mine related to pharmacy practice include extensive participation in the recent revision of the Pharm.D. curriculum at Minnesota, and serving as Grand Council

RECEIVED

DEC 29 2015

IOWA BOARD OF PHARMACY

UNIVERSITY OF MINNESOTA

Twin Cities Campus

*Department of Medicinal Chemistry
College of Pharmacy*

*308 Harvard Street S.E.
Room 8-121
Minneapolis, MN 55455*

*Robert A. Fecik
Associate Professor*


*Tel: 612-625-9335
E-mail: fecik001@umn.edu*

Deputy (faculty advisor) of the Kappa Psi Chapter for approximately ten years, which included responsibilities in advising students in therapy-related activities such as running the pharmacy at the free Phillips Neighborhood Clinic in Minneapolis and a kidney-screening program.

I ask for your consideration of these activities related to the practice of pharmacy in determining the extent of internship hours, if any, that you would require of me to reactivate my license.

I look forward to a productive meeting with you, and I am grateful for your help and guidance in this matter.

Sincerely,



Robert A. Fecik, Ph.D.
Associate Professor of Medicinal Chemistry

Robert Andrew Fecik, Ph.D.
Associate Professor
Department of Medicinal Chemistry
717 Delaware St. S.E., Room 456
Minneapolis, MN 55414-2959
University of Minnesota
612-625-9335 fecik001@umn.edu

EDUCATION

- 1999–2001 **American Cancer Society Postdoctoral Fellow**
The Scripps Research Institute, La Jolla, CA
Department of Chemistry and The Skaggs Institute for Chemical Biology
Advisor: *Dale L. Boger*
- 1999 **Ph.D., Medicinal Chemistry**
“Synthesis of Tricyclic Dihydroquinolone and Quinolone Antimicrobials”
University of Kansas, Lawrence, KS
Advisor: *Lester A. Mitscher*
- 1994 **B.S., Pharmacy**
University of Iowa, Iowa City, IA

EXPERIENCE

- 2009–2010 **Director of Graduate Studies**
University of Minnesota, Medicinal Chemistry Graduate Program
- 2007–present **Associate Professor**
University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN
Development of synthetic methods for the combinatorial biosynthesis of polyketide natural products particularly focused on pikromycin biosynthesis. Development of synthetic methods for the synthesis of tubulysins for multidrug-resistant cancers. Discovery of fatty acid synthase inhibitors for the chemoprevention and treatment of cancers.
- 2001–2007 **Assistant Professor**
University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN
- 1999–2001 **American Cancer Society Postdoctoral Fellow**
The Scripps Research Institute, Department of Chemistry and The Skaggs Institute for Chemical Biology, La Jolla, CA
Mechanism-based design and synthesis of α -ketoheterocycle inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of endocannabinoids.
- 1994–1999 **Graduate Research Assistant**
“Synthesis of Tricyclic Dihydroquinolone and Quinolone Antimicrobials”
University of Kansas, Department of Medicinal Chemistry, Lawrence, KS

Design and synthesis of tricyclic quinolone analogs to probe the effects of chirality in binding to DNA gyrase and topoisomerase IV.

- 1994 **R & D Summer Intern**
Abbott Laboratories, Immunoscience Discovery, Abbott Park, IL
Development of synthetic methods for a series of ascomycin analogs as immunosuppressants.
- 1994 **Pharmacy Extern**
Abbott Laboratories, Preformulation, Abbott Park, IL
Development of HPLC methods to analyze the thermal and photostability of zileuton (Zyflo[®]) metabolites.
- 1993 **Undergraduate Research Assistant**
The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, Columbus, OH
Advisor: *Donald T. Witiak*
Design and synthesis of 2-hydroxytetronic acid analogs of lipoic acid.
- 1992–1993 **Undergraduate Research Assistant**
University of Iowa, Department of Medicinal and Natural Products Chemistry, Iowa City, IA
Advisor: *Dee Ann Casteel*
Design and synthesis of artemisinin analogs as antimalarials.

TEACHING EXPERIENCE

- Phar 6154 Medicinal Agents I, Course Director (7 semesters)
9 semesters, 13 lectures/semester, ~160 students/semester
Topics taught: cardiovascular drugs
- Phar 6155 Medicinal Agents II
7 semesters, 7 lectures/semester, ~160 students/semester
Topics taught: psychiatric drugs
- Phar 6156 Medicinal Agents III
3 semesters, 15 lectures/semester, ~100 students/semester
Topics taught: anticancer drugs
- Phar 6182 Pharm.D. IV Seminar
10 semesters, ~3 students advised/semester
- Phar 6183 Pharm.D. IV Paper
10 semesters, ~3 students advised/semester
- MedC 5710/8002 General Principles of Medicinal Chemistry II
3 semesters, 3 lectures, 6 students
Topics taught: combinatorial chemistry
- MedC 8700/Chem 8700 Advanced Concepts in Medicinal Chemistry: Combinatorial Methods
in Chemical Biology
3 semesters, 6 lectures, ~12 students
Topics taught: combinatorial chemistry, combinatorial biosynthesis
- MedC 8420 Natural Products Chemistry
2 semesters, 18–30 lectures, 5–10 students

PROFESSIONAL AFFILIATIONS

Masonic Cancer Center, University of Minnesota
American Chemical Society
Medicinal Chemistry Division
Organic Division
Kappa Psi Pharmaceutical Fraternity

HONORS AND AWARDS

2010 Professor of the Semester, 2013 Pharm.D. Class (Twin Cities), College of Pharmacy, University of Minnesota
2010 Professor of the Semester, 2013 Pharm.D. Class (Duluth), College of Pharmacy, University of Minnesota
2009 Professor of the Semester, 2011 Pharm.D. Class (Twin Cities), College of Pharmacy, University of Minnesota
2007 Faculty of 1000 Biology, Pharmacology & Drug Discovery section.
2003 New Investigator Award, American Association of Colleges of Pharmacy
2002 Professor of the Semester, 2004 Pharm.D. Class, College of Pharmacy, University of Minnesota
1999–2001 American Cancer Society Postdoctoral Fellowship
1998 Irsay–Dahle Award for Excellence in Medicinal Chemistry, Department of Medicinal Chemistry, University of Kansas
1997–1999 NIH Predoctoral Training Grant Fellowship
1996–1997 Kansas Health Foundation Predoctoral Fellowship
1996 Rosenfeld Memorial Scholarship, School of Pharmacy, University of Kansas
1993 Zopf Memorial Scholarship, College of Pharmacy, University of Iowa
1989–1993 State of Iowa Scholar
1989 National Elks Foundation Scholarship
1989 Kiwanis Scholarship
1989 Good Citizenship Award, Daughters of the American Revolution
1987 Eagle Scout Award, Boy Scouts of America

EXTERNAL FUNDING (Direct Costs)

2010	Amgen, Inc. (2010–2012) <i>Tubulysin Analogues as Novel Antibody-Drug Conjugate Payloads</i>	\$129,054	Completed
2009	National Institute for General Medical Sciences (2009–2014) \$2,432,857 (project total, Janet L. Smith, PI), \$1,124,232 (subaward 1, Fecik, co-PI) R01 GM081544-01A2 <i>Structural Basis of Specificity in Affinity-labeled Polyketide Synthase Domains</i>	\$2,432,857	Current
2008	Department of Defense (2008–2009) Concept Award, Ovarian Cancer Research Program <i>Fatty Acid Synthase Inhibitors for the Treatment of Ovarian Cancer</i>	\$74,825	Completed
2005	American Cancer Society (2005–2009) Research Scholar Grant <i>Synthesis of Tubulysin D and Investigation of Its Tubulin Binding Site</i>	\$600,000	Completed

2004	1) Cystic Fibrosis Foundation (2004–2006) Pilot and Feasibility Award <i>Immunomodulatory Macrolides for Cystic Fibrosis</i>	\$86,400	Completed
	2) NaturNorth Technologies, LLC (2004–2005) Sponsored Research Award <i>Betulin Derivatives as Antifungal Agents</i>	\$23,860	Completed
2003	American Association of Colleges of Pharmacy (2003–2004) New Investigator Award <i>Discovery of FtsZ Polymerization Inhibitors as Novel Antibacterial Agents</i>	\$10,000	Completed
1998	American Cancer Society (1999–2001) Postdoctoral Scholar Fellowship <i>Design and Synthesis of Fatty Acid Amide Hydrolase Inhibitors</i>	\$100,000	Completed

INTERNAL FUNDING (Direct Costs)

2011	1) Cancer Center, University of Minnesota (2012–2013) Brainstorm Award <i>Mechanism of Action and Prodrugs of RITA, a Small Molecule for MLL Leukemias</i>	\$50,000	Completed
	2) Academic Health Center, University of Minnesota (2011–2012) Seed Grant <i>Mechanism of Action of RITA, a Small Molecule for MLL Leukemias</i>	\$25,000	Completed
2006	Office of Information Tech., Univ. of Minnesota (2006–2007) TEL Grant <i>A Pilot Study to Assess Video Podcasting, Streaming Video, and Audio Podcasting for Supplemental Learning for Students on Two Campuses</i>	\$14,800	Completed
	Cancer Center, University of Minnesota (2006–2007) Brainstorm Award <i>Estrogenic Regulators for the Prevention and Treatment of Prostate Cancer</i>	\$25,000	Completed
2004	Graduate School, University of Minnesota (2005–2006) Grant-In-Aid of Research, Artistry, and Scholarship <i>Identification of Novel Drug Targets for Cystic Fibrosis</i>	\$22,300	Completed
2002	Academic Health Center, University of Minnesota (2003–2004) Faculty Research Development Grant FRD 02-13 <i>Chemoenzymatic Synthesis of Ketolide Antibiotics</i>	\$234,000	Completed
2001	1) Graduate School, University of Minnesota (2002–2003) Grant-In-Aid of Research, Artistry, and Scholarship <i>Combinatorial Synthesis of Novel FtsZ Polymerization Inhibitors</i>	\$26,254	Completed
	2) Graduate School, University of Minnesota (2002–2003) Grant-In-Aid of Research, Artistry, and Scholarship <i>Fluorescence Spectrophotometer</i>	\$17,000	Completed

3) Cancer Center, University of Minnesota (2002) \$20,000 Completed
 American Cancer Society Institutional Grant Award
Determination of the Bioactive Conformations of Tubulysin D and Dolastatin 10

DEPARTMENTAL, COLLEGE, and UNIVERSITY SERVICE

Educational Policy and Peer Review Committee, College of Pharmacy	2013–present
Curriculum Revision Steering Committee, College of Pharmacy	2012–present
Graduate Retreat Committee, Department of Medicinal Chemistry	2012–2013
Curriculum Revision Discipline Area Leader, College of Pharmacy	2010–2011
Chair, Gisvold Symposium, Department of Medicinal Chemistry	2009
Advisory Board, Pharmacy Faculty Practice Group, College of Pharmacy	2008–2010
Chair, Educational Policy Committee, College of Pharmacy	2008–2009
Knowledge Assessment Sub-Committee, College of Pharmacy	2008–2009
NMR Advisory Committee, University of Minnesota	2008–2012
Curriculum Revision Task Force, College of Pharmacy	2007–2009
Pharmacy Practice & Pharmaceutical Sciences Department Head Search Committee	2007–2008
College of Pharmacy Senior Associate Dean for Professional Education Search Committee	2007–2008
Vice-Chair, Educational Policy Committee, College of Pharmacy	2007–2008
Medicinal Chemistry Faculty Search Committee	2007–2008
Combinatorial Chemistry Laboratory Search Committee	2006–2007
Chemistry Department Faculty Search Committee	2006–2007
Co-Head, Medicinal Chemistry Graduate Recruitment Committee	2006–2013
Curriculum Working Group, College of Pharmacy	2005–2006
Educational Policy Committee, College of Pharmacy	2004–2010
Professional Education Strategic Planning Committee	2004–2005
Medicinal Chemistry Department Head Search Committee	2004–2005
Medicinal Chemistry Faculty Search Committee	2001–2003
Medicinal Chemistry Faculty (Duluth) Search Committee	2001–2003
Organizing Committee, Abbott Workshops in Synthetic Organic Medicinal Chemistry, Department of Chemistry	2003–present
Grand Council Deputy (Faculty Advisor), Kappa Psi Pharmaceutical Fraternity	2002–2013
Interviewer, Pharm.D. Admissions Committee	2002–2009
Grant Reviewer for Academic Health Center	2003, 2005
2005 MIKI Meeting, Faculty Liaison	2004–2005
Major Instrumentation: Solvent Purification Systems Liaison	2003–2004

SCIENTIFIC COMMUNITY SERVICE

Member, Peer Review Committee on Cancer Drug Discovery, American Cancer Society	2012–2015
American Association of Colleges of Pharmacy, New Investigator Award Reviewer	2012
Co-Chair, Mitscher Symposium Organizing Committee, Lawrence, KS	2010–2011
NIH P30 Grant Reviewer	2010
American Cancer Society Grant Reviewer, Ad Hoc	2010–2011
OTC Case Judge, Minnesota Student Pharmacists Association	2010–2011
Chair, Allosteric Ligands, European Federation for Medicinal Chemistry Meeting	2010
Co-Chair, Novel Ophthalmic Therapeutics, 240th ACS National Meeting,	2010

Boston, MA	
Co-Chair, Novel Therapeutics for the Treatment of Insomnia, 238th ACS National Meeting, Washington, DC	2009
Killam Research Fellowship Reviewer, Canada Council for the Arts	2008
Co-Chair, Fatty Acid Synthase Inhibitors Session, 235th ACS National Meeting, New Orleans, LA	2008
Department of Defense Grant Reviewer, Breast Cancer Program	2008
Department of Defense Grant Reviewer, Prostate Cancer Program	2007
National Science Foundation Grant Reviewer, Division of Chemistry	2007–2009
Long Range Planning Committee, Division of Medicinal Chemistry, American Chemical Society	2007–2010
National Institutes of Health, Center for Scientific Review Special Emphasis Panel, ZRG1 F04A-D (20), Chemical and Bioanalytical Sciences	2006

Manuscript referee for:

ACS Chemistry Neuroscience
ACS Medicinal Chemistry Letters
Biochemical Pharmacology
Bioorganic and Medicinal Chemistry Letters
Chemistry & Biology
ChemMedChem
Current Medicinal Chemistry
European Journal of Medicinal Chemistry
Journal of the American Chemical Society
Journal of Biological Chemistry
Journal of Enzyme Inhibition and Medicinal Chemistry
Journal of Medicinal Chemistry
Journal of Natural Products
Journal of Organic Chemistry
Journal of the American Chemical Society
Marine Drugs
Microbiology
Molecular Pharmaceutics
Nature Chemical Biology
Organic & Bioorganic Chemistry
Organic Letters
Synthesis
Tetrahedron
Tetrahedron Letters

PATENTS

1. U.S. Provisional Patent Application, “Methods of Making Narbonolide and Analogs Thereof”, August 2, **2005**. (Abandoned)
2. U.S. Provisional Patent Application, “Novel Tubulysin Analogs”, October 14, **2013**.
3. U.S. Provisional Patent Application, “Novel Nitrogen-Based Tubulysin Analogs”, October 14, **2013**.

INVITED PRESENTATIONS

- 2013 37. University of Minnesota, Masonic Cancer Center, Minneapolis, MN
- 2012 36. Gustavus Adolphus College, Department of Chemistry, St. Peter, MN
- 2011 35. University of Kansas, Department of Medicinal Chemistry, Lester A. Mitscher Symposium, Lawrence, KS
- 2010 34. Temple University, Department of Chemistry, Philadelphia, PA
33. University of Minnesota, Masonic Cancer Center, Minneapolis, MN
- 2009 32. University of Minnesota, Gisvold Symposium on Natural Products, Minneapolis, MN
31. American Cancer Society, Minnesota Chapter Researchers Breakfast, Minneapolis, MN
30. University of Northern Iowa, Department of Chemistry, Cedar Falls, IA
29. American Chemical Society National Meeting, Washington DC
- 2008 28. University of Minnesota, Women's Cancer Interest Group, Minneapolis, MN
27. Syracuse University, Department of Chemistry, Syracuse, NY
- 2007 26. Engebretson Symposium in Drug Discovery and Development in Natural Products, University of Minnesota, Minneapolis, MN
25. American Cancer Society, Making Strides Against Breast Cancer Kickoff, Minneapolis, MN
24. San Diego State University, Department of Chemistry and Biochemistry, San Diego, CA
23. University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, CA
22. Michigan State University, Department of Chemistry, East Lansing, MI
21. University of Wisconsin, Division of Pharmaceutical Sciences, Madison, WI
20. University of Iowa, Division of Medicinal and Natural Products Chemistry, Iowa City, IA
19. Edina Morningside Rotary Club, Edina, MN
- 2006 18. University of Minnesota, Academic and Distributed Computing Services and the Digital Media Center, Minneapolis, MN
17. University of Michigan, Center for Chemical Genomics, Ann Arbor, MI
16. St. Cloud State University, Department of Chemistry, St. Cloud, MN
15. American Association of Colleges of Pharmacy Annual Meeting, San Diego, CA
14. Chemical Biology Symposium, University of Minnesota, Minneapolis, MN
13. Brigham Young University, Department of Chemistry, Provo, UT
12. University of Utah, Department of Medicinal Chemistry, Salt Lake City, UT
11. 7th Winter Conference on Medicinal & Bioorganic Chemistry, Clearwater Beach, FL
- 2005 10. Ripon College, Department of Chemistry, Ripon, WI
9. American Cancer Society Relay for Life Midwest Youth Summit, Minneapolis, MN
8. Engebretson Symposium on Drug Discovery and Development in Cancer Experimental Therapeutics, College of Pharmacy and Cancer Center, University of Minnesota, Minneapolis, MN
7. 3M Pharmaceuticals Division, St. Paul, MN
6. 6th Winter Conference on Medicinal & Bioorganic Chemistry, Steamboat Springs, CO
- 2003 5. University of Minnesota-Duluth, Department of Chemistry, Duluth, MN
4. Carleton College, Department of Chemistry, Northfield, MN
- 2002 3. University of Minnesota, Department of Veterinary & Biomedical Sciences, Minneapolis, MN
2. Engebretson Symposium, Mayo Clinics, Rochester, MN
1. Chemical Biology Colloquium, University of Minnesota, Minneapolis, MN

POSTER AND OTHER PRESENTATIONS

23. Gordon Research Conference on Natural Products, Onorato, A.; Leggans, E.; Akey, D. A.; Smith, J. L.; Fecik, R. A. Labels for Polyketide Synthase Didomains. Tilton School, Tilton, NH, July 27, **2010**.
22. MIKI Medicinal Chemistry Meeting-in-Miniature, Peterson, M.; Raghavan, B.; Balasubramanian, R.; Fecik, R. A.; Sackett, D. L. Recent Synthesis and Biological Evaluation of Tubulysin Analogs. Chicago, IL, April 10, **2010**.
21. MIKI Medicinal Chemistry Meeting-in-Miniature, Leggans, E.; Fecik, R. A. Design and Synthesis of Labels for Polyketide Synthase Didomains. Chicago, IL, April 10, **2010**.
20. Gordon Research Conference on Natural Products, Leggans, E.; Fecik, R. A. Design and Synthesis of Polyketide-Based Affinity Labels for Acyl Carrier Proteins. Tilton School, Tilton, NH, July 24, **2009**.
19. Gordon Research Conference on Natural Products, Fecik, R. A. Total Synthesis of Tubulysins and Determination of Structural Requirements for Multidrug-Resistant Anticancer Activity. Tilton School, Tilton, NH, July 20, **2008**.
18. MIKI Medicinal Chemistry Meeting-in-Miniature, Leggans, E.; Fecik, R. A. Design and Synthesis of Polyketide-based Affinity Labels for Acyl Carrier Protein Domains. Iowa City, IA, April 26, **2008**.
17. 235th ACS National Meeting, Leggans, E.; Fecik, R. A. Design and Synthesis of Polyketide-based Affinity Labels for Acyl Carrier Protein Domains. New Orleans, LA, April 6–10, **2008**.
16. 235th ACS National Meeting, Balasubramanian, R.; Raghavan, B.; Fecik, R. A. Probing the Structure–Activity Relationships of Tubulysins. New Orleans, LA, April 6–10, **2008**.
15. Gordon Research Conference on Bioorganic Chemistry, Fecik, R. A.; Leggans, E. Design and Synthesis of Affinity Labels for Polyketide Synthase Didomains. Proctor Academy, Andover, NH, June 13, **2007**.
14. MIKI Medicinal Chemistry Meeting-in-Miniature, Leggans, E.; Fecik, R. A.; Giraldes, J. W. Polyketide Synthase Affinity Labels for Combinatorial Biosynthesis. Lawrence, KS, April 14, **2007**.
13. MIKI Medicinal Chemistry Meeting-in-Miniature, Balasubramanian, R.; Raghavan, B.; Steele, J. C.; Fecik, R. A. Synthetic Studies on the Tubulysins, a Potent Class of Tubulin Polymerization Inhibitors. Lawrence, KS, April 14, **2007**.
12. 8th Winter Conference on Medicinal & Bioorganic Chemistry, Giraldes, J. G.; Lakshmanan, V.; Leggans, E.; Fecik, R. A. Polyketide Synthase Affinity Labels for Combinatorial Biosynthesis. Steamboat Springs, CO, January 24, **2007**.
11. 8th Winter Conference on Medicinal & Bioorganic Chemistry, Raghavan, B.; Balasubramanian, R.; Steele, J. C.; Fecik, R. A. Synthetic Studies on the Tubulysins, a Potent Class of Tubulin Polymerization Inhibitors. Steamboat Springs, CO, January 24, **2007**.
10. 7th Winter Conference on Medicinal & Bioorganic Chemistry, Steele, J. C.; Fecik, R. A.; Jansma, M. Synthesis of Tubulysin Analogs as Potential Tubulin Polymerization Inhibitors. Clearwater Beach, FL, February 27, **2006**.
9. Life Sciences Summer Undergraduate Research Programs Symposium, Jansma, M.; Fecik, R. A. The Synthesis of Tubuvaline Fragments for Incorporation into Tubulysin Analogs. St. Paul, MN, August 12, **2005**.
8. University of Minnesota Summer Undergraduate Research Symposium, Rogers, P.; Fecik, R. A. Synthesis of Tubulysin Analogs as Potential Anti-Cancer Drugs. Minneapolis, MN, August 11, **2005**.
7. Engebretson Symposium on Drug Discovery and Development in Cancer Experimental Therapeutics, Steele, J. C.; Venkatraman, L.; Aldrich, C. C.; Fecik, R. A. Progress Towards the Synthesis of Tubulysin D. Minneapolis, MN, June 9, **2005**.
6. MIKI Medicinal Chemistry Meeting-in-Miniature, Steele, J. C.; Venkatraman, L.; Aldrich, C. C.; Fecik, R. A. Progress Towards the Synthesis of Tubulysin D. Minneapolis, MN, June 3–5, **2005**.

5. MIKI Medicinal Chemistry Meeting-in-Miniature, Nguyen, P. L.; Fecik, R. A. Synthesis of Biotinylated Macrolide Derivatives for Use in Identifying Novel Binding Proteins. Minneapolis, MN, June 3–5, **2005**.
4. 6th Winter Conference on Medicinal & Bioorganic Chemistry, Steele, J. C.; Venkatraman, L.; Aldrich, C. C.; Fecik, R. A. The Total Synthesis of Tubulysin D. Steamboat Springs, CO, January 23–28, **2005**.
3. 228th ACS National Meeting, Venkatraman, L.; Aldrich, C. C.; Fecik, R. A. Total Synthesis of Narbonolide and Ketolide Antibiotics. Sci-Mix and ORGN-384, Philadelphia, PA, August 22–26, **2004**.
2. Engebretson Symposium, Steele, J. C.; Fecik, R. A. Progress Towards the Total Synthesis of Tubulysin D. Fargo, ND, May 10–11, **2004**.
1. Engebretson Symposium, Nguyen, P. L.; Fecik, R. A. Synthesis of Macrolide Derivatives for Use in Identifying Novel Binding Proteins. Fargo, ND, May 10–11, **2004**.

PUBLICATIONS

25. Peterson, M. T.; Balasubramanian, R.; Raghavan, B.; Sackett, D. L.; Fecik, R. A. Exceptionally Potent Tubulysin Analogs for Targeted Drug Delivery. *In preparation*.
24. Li, Y.; Fiers, W. D.; Aldrich, C. C.; Fecik, R. A. Polyketide Intermediate Mimics – Probing the Substrate and Stereospecificity of Ketoreductase in Pikromycin Module 2. *In preparation*.
23. Murray, B. C.; Peterson, M. T.; Fecik, R. A. Chemistry and Biology of Tubulysins: Antimitotic Tetrapeptides with Activity against Drug Resistant Cancers. *In preparation*.
22. Leggans, E. K.; Akey, D. L.; Smith, J. L.; Fecik, R. A. A General Scheme for Synthesis of Substrate-based Polyketide Labels for Acyl Carrier Proteins. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 5939–5942.
21. Balasubramanian, R.; Raghavan, B.; Begaye, A. Sackett, D. L.; Fecik, R. A. Total Synthesis and Biological Evaluation of Tubulysin U, Tubulysin V, and their Analogues. *J. Med. Chem.* **2009**, *52*, 238–240.
20. Gupta, S.; Venkatraman, L.; Kim, B. S.; Fecik, R. A.; Reynolds, K. A. Generation of Novel Pikromycin Antibiotic Products through Mutasynthesis. *ChemBioChem* **2008**, *9*, 1609–1616.
19. Balasubramanian, R.; Raghavan, B.; Sackett, D. L.; Fecik, R. A. Tubulysin Analogs Incorporating Desmethyl and Dimethyl Tubuphenylalanine Derivatives. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2996–2999.
18. Raghavan, B.; Balasubramanian, R.; Steele, J. C.; Sackett, D. L.; Fecik, R. A. Cytotoxic Simplified Tubulysin Analogs. *J. Med. Chem.* **2008**, *51*, 1530–1533.
17. Fecik, R. A. Natural Product Biosynthesis Moves *in Vitro*. *Nat. Chem. Biol.* **2007**, *3*, 531–532.
16. Venkatraman, L.; Salomon, C. E.; Sherman, D. H.; Fecik, R. A. Total Synthesis of Narbonolide and Biotransformation to Pikromycin. *J. Org. Chem.* **2006**, *71*, 9853–9856.
15. Akey, D. L.; Kittendorf, J. D.; Giralde, J. W.; Fecik, R. A.; Sherman, D. H.; Smith, J. L. Structural Basis for Macrolactonization by the Pikromycin Thioesterase. *Nat. Chem. Biol.* **2006**, *2*, 537–542.
14. Giralde, J. W.; Akey, D. L.; Kittendorf, J. D.; Sherman, D. H.; Smith, J. L.; Fecik, R. A. Structural and Mechanistic Insights of Polyketide Macrolactonization from Polyketide-based Affinity Labels. *Nat. Chem. Biol.* **2006**, *2*, 531–536.
13. Fecik, R. A.; Nguyen, P. L.; Venkatraman, L. Approaches to the Synthesis of Immunolides: Selective Immunomodulatory Macrolides for Cystic Fibrosis. *Curr. Opin. Drug Disc. Dev.* **2005**, *8*, 741–747.
12. Venkatraman, L.; Aldrich, C. C.; Sherman, D. H.; Fecik, R. A. Formal Total Synthesis of the Polyketide-derived Macrolactone Narbonolide. *J. Org. Chem.* **2005**, *70*, 7267–7272.
11. Aldrich, C. C.; Venkatraman, L.; Sherman, D. H.; Fecik, R. A. Chemoenzymatic Synthesis of the Polyketide Macrolactone 10-Deoxymethynolide. *J. Am. Chem. Soc.* **2005**, *127*, 8910–8911.

10. Aldrich, C. C.; Beck, B. J.; Fecik, R. A.; Sherman, D. H. Biochemical Investigation of Pikromycin Biosynthesis Employing Native Penta- and Hexaketide Chain Elongation Intermediates. *J. Am. Chem. Soc.* **2005**, *127*, 8441–8452.
9. Beck, B. J.; Aldrich, C. C.; Fecik, R. A.; Reynolds, K. A.; Sherman, D. H. Substrate Recognition and Channeling of Monomodules from the Pikromycin Polyketide Synthase. *J. Am. Chem. Soc.* **2003**, *125*, 12551–12557.
8. Beck, B. J.; Aldrich, C. C.; Fecik, R. A.; Reynolds, K. A.; Sherman, D. H. Iterative Chain Elongation by a Pikromycin Monomodular Polyketide Synthase. *J. Am. Chem. Soc.* **2003**, *125*, 4682–4683.
7. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimarães, C. R. Q.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a Potent, Selective, and Efficacious Class of Reversible α -Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Effective as Analgesics. *J. Med. Chem.* **2005**, *48*, 1849–1856.
6. Fedorova, I.; Hashimoto, A.; Fecik, R. A.; Hedrick, M. P.; Hanus, L. O.; Boger, D. L.; Rice, K. C.; Basile, A. S. Behavioral Evidence for the Interaction of Oleamide with Multiple Neurotransmitter Systems. *J. Pharmacol. Exp. Ther.* **2001**, *299*, 332–342.
5. Boger, D. L.; Fecik, R. A.; Patterson, J. E.; Miyauchi, H.; Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Substrate Specificity. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 4645–4648.
4. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally Potent Inhibitors of Fatty Acid Amide Hydrolase. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 5044–5049.
3. Fecik, R. A.; Devasthale, P.; Pillai, S.; Keschavarz-Shokri, A.; Shen, L.; Mitscher, L. A. Chiral DNA Gyrase Inhibitors. 3. Probing the Chiral Preference of the Active Site of DNA Gyrase. Synthesis of 10-Fluoro-6-methyl-6,7-dihydro-9-piperazinyl-2*H*-benzo[*a*]quinolizine-20-one-3-carboxylic Acid Analogues. *J. Med. Chem.* **2005**, *48*, 1229–1236.
2. Fecik, R. A.; Frank, K. E.; Gentry, E. J.; Mitscher, L. A.; Shibata, M. Use of Combinatorial and Multiple Parallel Synthesis Methodologies for the Development of Anti-Infective Natural Products. *Pure Appl. Chem.* **1999**, *71*, 559–564.
1. Fecik, R. A.; Frank, K. E.; Gentry, E. J.; Menon, S. J.; Mitscher, L. A.; Telikepalli, H. The Search for Orally Active Medications through Combinatorial Chemistry. *Med. Res. Rev.* **1998**, *18*, 149–185.

CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

DRUG STORE NEWS
CONTINUING EDUCATION PROGRAM
PO BOX 31180, TAMPA, FL 33631-3180



DRUG STORE NEWS is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

UNIVERSAL PROGRAM NUMBER

401-000-02-018-H01

Supported by: Johnson & Johnson

LESSON NUMBER: 02-018
CREDIT HOURS: 2
DATE RECEIVED: 20040105

- 1. C 2. B 3. A 4. D 5. C
- 6. A 7. D 8. C 9. B 10. B
- 11. D 12. A 13. B 14. C 15. B
- 16. B 17. C 18. D 19. A 20. D

LESSON: Wounds and bandages: old problems/new solutions

ENROLLMENT# 5347758

Authorized
Signature:

A handwritten signature in cursive script, appearing to read 'Kimberly K. Weyner', written over a horizontal line.

ROBERT FECIK
UNIVERSITY OF MINNESOTA
308 HARVARD ST. S.E.
8-101 WDH
MINNEAPOLISMN 55455

DATE: 01/05/2004

01052004170817

**STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT**

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist

ACPE I.D.

430-000-02-012-H01**PROGRAM INFORMATION**

TITLE:

The Effects of Genetic Disposition on Drug Response

EXAM SUBMITTED ON:

1/6/04

EXAM PROCESSED ON:

1/6/04**PARTICIPANT INFORMATION**

NAME:

Fecik, Robert A

ADDRESS:

308 Harvard St. S.E., 8-101 WDH

CITY, STATE, ZIP:

Minneapolis, MN 55455**CREDIT INFORMATION**

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: 1 19

STATEMENT ISSUED ON: 1/6/04

ORIGINAL CERTIFICATEAUTHORIZED
SIGNATURE



Dear Participant:

Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

**CONTINUING PHARMACEUTICAL
EDUCATION STATEMENT OF CREDIT**

This certifies that

Robert A. Fecik

has successfully completed the program

Achieving Blood Pressure Goals: Is Fixed-Dose Combination Therapy the Answer?

ACPE Universal Program I.D. No. 290-999-03-009-H01

and earned 1.5 contact hours (0.15 CEUs) on 1/8/2004



Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Fred M. Eckel, RPh, MS
Editor-in-Chief



Dear Participant:

Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Opioid Use in Clinical Practice

ACPE Universal Program I.D. No. 290-000-03-001-H01

and earned 2.5 contact hours (0.25 CEUs) on 1/8/2004



Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Fred M. Eckel, RPh, MS
Editor-in-Chief

**STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT**

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist

ACPE I.D.

430-000-03-025-H01**PROGRAM INFORMATION**

TITLE:

Drug Interactions of Antifungal Agents in Transplant Patients

EXAM SUBMITTED ON:

1/6/04

EXAM PROCESSED ON:

1/6/04**PARTICIPANT INFORMATION**

NAME:

Fecik, Robert A

ADDRESS:

308 Harvard St. S.E., 8-101 WDH

CITY, STATE, ZIP:

Minneapolis, MN 55455**CREDIT INFORMATION**

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: None

STATEMENT ISSUED ON: 1/6/04

ORIGINAL CERTIFICATEAUTHORIZED
SIGNATURE



STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist

ACPE I.D.

430-000-03-011-H01

PROGRAM INFORMATION

TITLE:

New Options in the Treatment of Depression

EXAM SUBMITTED ON:

1/7/04

EXAM PROCESSED ON:

1/7/04

PARTICIPANT INFORMATION

NAME:

Fecik, Robert A

ADDRESS:

308 Harvard St. S.E., 8-101 WDH

CITY, STATE, ZIP:

Minneapolis, MN 55455

CREDIT INFORMATION

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: None

STATEMENT ISSUED ON: 1/7/04

ORIGINAL CERTIFICATE

AUTHORIZED SIGNATURE

[Handwritten Signature]





STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

**U.S. Pharmacist
ACPE I.D.
430-000-03-009-H01**

PROGRAM INFORMATION

TITLE:

**Management of Attention Deficit/
Hyperactivity Disorder in Children and
Adults**

EXAM SUBMITTED ON:

1/6/04

EXAM PROCESSED ON:

1/6/04

PARTICIPANT INFORMATION

NAME:

Fecik, Robert A

ADDRESS:

**308 Harvard St. S.E., 8-101 WDH
CITY, STATE, ZIP:
Minneapolis, MN 55455**

CREDIT INFORMATION

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: 20

STATEMENT ISSUED ON: 1/6/04

ORIGINAL CERTIFICATE

AUTHORIZED
SIGNATURE

[Handwritten Signature]





Dear Participant:


Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

	<p>CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT</p>
--	---

This certifies that



Robert A. Fecik

has successfully completed the program

Drug interactions and statin safety: a major factor in selection of therapy

ACPE Universal Program I.D. No. 290-999-03-005-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/2/2004

 <p>Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.</p>	 <p>Fred M. Eckel, RPh, MS Editor-in-Chief</p>
--	--

**STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT**

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist

ACPE I.D.

430-000-03-059-H01**PROGRAM INFORMATION**

TITLE:

The Role of Proton Pump Inhibitors in the Management of GERD

EXAM SUBMITTED ON:

1/6/04

EXAM PROCESSED ON:

1/6/04**PARTICIPANT INFORMATION**

NAME:

Fecik, Robert A

ADDRESS:

308 Harvard St. S.E., 8-101 WDH

CITY, STATE, ZIP:

Minneapolis, MN 55455**CREDIT INFORMATION**

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: 15 16

STATEMENT ISSUED ON: 1/6/04

ORIGINAL CERTIFICATEAUTHORIZED
SIGNATURE



Dear Participant:

Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Medical Management of Peripheral Arterial Disease

ACPE Universal Program I.D. No. 290-000-03-012-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004



Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Fred M. Eckel, RPh, MS
Editor-in-Chief



Dear Participant:


Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

	<p>CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT</p>
--	---

This certifies that



Robert A. Fecik

has successfully completed the program

Periodontal Disease and Diabetes: Identifying Complications, Optimizing Disease Management

ACPE Universal Program I.D. No. 290-000-03-010-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/8/2004

 <p>Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.</p>	 <p>Fred M. Eckel, RPh, MS Editor-in-Chief</p>
--	--



STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

**U.S. Pharmacist
ACPE I.D.
430-000-03-021-H01**

PROGRAM INFORMATION

TITLE:

**Advances in Adjunctive Pharmacotherapy
for Patients Undergoing PCI
EXAM SUBMITTED ON:
1/7/04
EXAM PROCESSED ON:
1/7/04**

PARTICIPANT INFORMATION

NAME:

**Fecik, Robert A
ADDRESS:
308 Harvard St. S.E., 8-101 WDH
CITY, STATE, ZIP:
Minneapolis, MN 55455**

CREDIT INFORMATION

CREDITS EARNED:

**0.2 CEU or 2 CREDIT HOURS
QUESTIONS MISSED: 3 6 10 15 18
STATEMENT ISSUED ON: 1/7/04**

ORIGINAL CERTIFICATE

AUTHORIZED SIGNATURE

[Handwritten Signature]



**STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT**

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist

ACPE I.D.

430-000-03-002-H01**PROGRAM INFORMATION**

TITLE:

Management of Pancreatic Exocrine Insufficiency

EXAM SUBMITTED ON:

1/7/04

EXAM PROCESSED ON:

1/7/04**PARTICIPANT INFORMATION**

NAME:

Fecik, Robert A

ADDRESS:

308 Harvard St. S.E., 8-101 WDH

CITY, STATE, ZIP:

Minneapolis, MN 55455**CREDIT INFORMATION**

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: None

STATEMENT ISSUED ON: 1/7/04

ORIGINAL CERTIFICATEAUTHORIZED
SIGNATURE
[Handwritten Signature]



Dear Participant:


Pharmacy Times and Temple University School of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Oral Lesions: Treatment and Identification

ACPE Universal Program I.D. No. 057-999-01-010-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/8/2004



Temple University School of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Peter H. Doukas, Ph.D
Dean, Temple University School of Pharmacy



Dear Participant:


Pharmacy Times and Temple University School of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Advances in the Therapy of Onychomycosis



ACPE Universal Program I.D. No. 057-999-01-033-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/8/2004



Temple University School of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Peter H. Doukas, Ph.D
Dean, Temple University School of Pharmacy

	
STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT	
100 Avenue of the Americas, New York, NY 10013	
<u>PROVIDER INFORMATION</u>	<u>PROGRAM INFORMATION</u>
NAME: U.S. Pharmacist ACPE I.D. 430-000-03-065-H01	TITLE: Neuropathic Pain Pathophysiology, Treatment and Patient Management EXAM SUBMITTED ON: 1/6/04 EXAM PROCESSED ON: 1/6/04
<u>PARTICIPANT INFORMATION</u>	<u>CREDIT INFORMATION</u>
NAME: Fecik, Robert A ADDRESS: 308 Harvard St. S.E., 8-101 WDH CITY, STATE, ZIP: Minneapolis, MN 55455	CREDITS EARNED: 0.2 CEU or 2 CREDIT HOURS QUESTIONS MISSED: 7 15 18 19 STATEMENT ISSUED ON: 1/6/04
	ORIGINAL CERTIFICATE
	 AUTHORIZED SIGNATURE <i>X [Signature]</i>



Dear Participant:

Pharmacy Times and Council of Ohio Colleges of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Counseling Patients about Lipid Management. Part I. What Are the Goals of Therapy?

ACPE Universal Program I.D. No. 105-999-03-908-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004



Council of Ohio Colleges of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Thomas W. O'Connor, Pharm.D., MBA
Professor of Pharmacy Practice
Director, Division of Continuing Pharmaceutical Education
Temple University School of Pharmacy



Dear Participant:


Pharmacy Times and Council of Ohio Colleges of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



This certifies that


Robert A. Fecik

has successfully completed the program

Counseling Patients about Lipid Management. Part II. Achieving LDL Goals in Clinical Practice

ACPE Universal Program I.D. No. 105-999-03-912-HO1

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004





Dear Participant:


Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

	<p>CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT</p>
--	---

This certifies that



Robert A. Fecik

has successfully completed the program

Review of Insomnia: The Sleep Cycle and Treatment Options

ACPE Universal Program I.D. No. 290-000-03-002-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/2/2004

 <p>Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.</p>	 <p>Fred M. Eckel, RPh, MS Editor-in-Chief</p>
--	--

CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

DRUG STORE NEWS
CONTINUING EDUCATION PROGRAM
PO BOX 31180, TAMPA, FL 33631-3180



DRUG STORE NEWS is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

UNIVERSAL PROGRAM NUMBER

401-000-01-022-H01

Supported by: Organon

LESSON NUMBER: 01-022
CREDIT HOURS: 2
DATE RECEIVED: 20040105

- 1. B 2. B 3. C 4. D 5. C
- 6. C 7. D 8. C 9. B 10. A
- 11. C 12. B 13. C 14. D 15. A
- 16. C 17. D 18. D 19. B 20. C

LESSON: Review of infertility treatment options

ENROLLMENT# 5347758

Authorized
Signature:

A handwritten signature in cursive script, appearing to read 'Kimberly K. Werner', written over a horizontal line.

ROBERT FECIK
UNIVERSITY OF MINNESOTA
308 HARVARD ST. S.E.
8-101 WDH
MINNEAPOLISMN 55455

DATE: 01/05/2004

01052004170409



Dear Participant:

Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

	CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT
--	--

This certifies that



Robert A. Fecik

has successfully completed the program

Pharmacists' Role in Recognizing and Managing Patients with Irritable Bowel Syndrome

ACPE Universal Program I.D. No. 290-000-03-004-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/2/2004

 <p>Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.</p>	 <p>Fred M. Eckel, RPh, MS Editor-in-Chief</p>
--	--



Dear Participant:

Pharmacy Times and Council of Ohio Colleges of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Management of Hypothyroidism

ACPE Universal Program I.D. No. 105-999-03-906-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/3/2004



Council of Ohio Colleges of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Thomas W. O'Connor, Pharm.D., MBA
Professor of Pharmacy Practice
Director, Division of Continuing Pharmaceutical
Education
Temple University School of Pharmacy

CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

DRUG STORE NEWS
CONTINUING EDUCATION PROGRAM
PO BOX 31180, TAMPA, FL 33631-3180



DRUG STORE NEWS is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

UNIVERSAL PROGRAM NUMBER

401-000-03-013-H01

Supported by: AstraZeneca

LESSON NUMBER: 03-013
CREDIT HOURS: 2
DATE RECEIVED: 20040105

- 1. C 2. A 3. A 4. D 5. B
- 6. C 7. C 8. A 9. B 10. D
- 11. B 12. A 13. C 14. B 15. B
- 16. D 17. C 18. D 19. C 20. D

LESSON: Update on the management of hypertension

ENROLLMENT# 5347758

Authorized
Signature:

A handwritten signature in cursive script, appearing to read 'Kimberly K. Werner', written over a horizontal line.

ROBERT FECIK
UNIVERSITY OF MINNESOTA
308 HARVARD ST. S.E.
8-101 WDH
MINNEAPOLISMN 55455

DATE: 01/05/2004

01052004142834



STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

**U.S. Pharmacist
ACPE I.D.
430-000-03-060-H01**

PROGRAM INFORMATION

TITLE:

**Self-Care of Heartburn: The Role of the
Pharmacist
EXAM SUBMITTED ON:
1/6/04
EXAM PROCESSED ON:
1/6/04**

PARTICIPANT INFORMATION

NAME:

**Fecik, Robert A
ADDRESS:
308 Harvard St. S.E., 8-101 WDH
CITY, STATE, ZIP:
Minneapolis, MN 55455**

CREDIT INFORMATION

CREDITS EARNED:

**0.2 CEU or 2 CREDIT HOURS
QUESTIONS MISSED: 8 15
STATEMENT ISSUED ON: 1/6/04**

ORIGINAL CERTIFICATE

AUTHORIZED
SIGNATURE

[Handwritten Signature]



**STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT**

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist
ACPE I.D.
430-000-02-193-H01

PROGRAM INFORMATION

TITLE:

**Managing Osteoarthritis: Focusing on
COX-2 Specific Inhibitors**
EXAM SUBMITTED ON:
1/7/04
EXAM PROCESSED ON:
1/7/04

PARTICIPANT INFORMATION

NAME:

Fecik, Robert A
ADDRESS:
308 Harvard St. S.E., 8-101 WDH
CITY, STATE, ZIP:
Minneapolis, MN 55455

CREDIT INFORMATION

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS
QUESTIONS MISSED: None
STATEMENT ISSUED ON: 1/7/04

ORIGINAL CERTIFICATEAUTHORIZED
SIGNATURE
[Signature]



Dear Participant:


Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

	<p>CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT</p>
--	---

This certifies that



Robert A. Fecik

has successfully completed the program

"Oh No, Not Another One-" Treatment and Prevention of the Common Cold

ACPE Universal Program I.D. No. 290-000-03-011-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004

 <p>Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.</p>	 <p>Fred M. Eckel, RPh, MS Editor-in-Chief</p>
--	--

CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

DRUG STORE NEWS
CONTINUING EDUCATION PROGRAM
PO BOX 31180, TAMPA, FL 33631-3180



DRUG STORE NEWS is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

UNIVERSAL PROGRAM NUMBER
401-000-02-016-H01

Supported by: Wyeth Consumer Healthcare

LESSON NUMBER: 02-016
CREDIT HOURS: 2
DATE RECEIVED: 20040105

- 1. B 2. A 3. C 4. B 5. D
- 6. C 7. A 8. C 9. D 10. D
- 11. C 12. B 13. C 14. A 15. D
- 16. B 17. A 18. C 19. A 20. D

LESSON: Prevention and early detection of colon cancer

ENROLLMENT# 5347758

Authorized
Signature:

A handwritten signature in cursive script, appearing to read 'Kimberly K. Werner', written over a horizontal line.

ROBERT FECIK
UNIVERSITY OF MINNESOTA
308 HARVARD ST. S.E.
8-101 WDH
MINNEAPOLISMN 55455

DATE: 01/05/2004

01052004143753



Dear Participant:


Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455

	<p>CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT</p>
--	---

This certifies that



Robert A. Fecik

has successfully completed the program

Cation Replacement in Diuretic Therapy

ACPE Universal Program I.D. No. 290-000-03-003-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004

 <p>Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.</p>	 <p>Fred M. Eckel, RPh, MS Editor-in-Chief</p>
--	--

**STATEMENT OF CONTINUING PHARMACEUTICAL EDUCATION CREDIT**

100 Avenue of the Americas, New York, NY 10013

PROVIDER INFORMATION

NAME:

U.S. Pharmacist

ACPE I.D.

430-000-02-013-H01**PROGRAM INFORMATION**

TITLE:

Benign Prostatic Hyperplasia

EXAM SUBMITTED ON:

1/6/04

EXAM PROCESSED ON:

1/6/04**PARTICIPANT INFORMATION**

NAME:

Fecik, Robert A

ADDRESS:

308 Harvard St. S.E., 8-101 WDH

CITY, STATE, ZIP:

Minneapolis, MN 55455**CREDIT INFORMATION**

CREDITS EARNED:

0.2 CEU or 2 CREDIT HOURS

QUESTIONS MISSED: 5

STATEMENT ISSUED ON: 1/6/04

ORIGINAL CERTIFICATEAUTHORIZED
SIGNATURE
Angela C. D'Angelo



Dear Participant:

Pharmacy Times is pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Antithrombotic Therapy for the Treatment of Venous Thromboembolism

ACPE Universal Program I.D. No. 290-000-03-008-H01

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004



Pharmacy Times is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Fred M. Eckel, RPh, MS
Editor-in-Chief



Dear Participant:


Pharmacy Times and Temple University School of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

Pharmaceutical Patent and Exclusivity Complexity: Implications for Generic Product Introductions

ACPE Universal Program I.D. No. 057-999-02-021-H03

and earned 2.0 contact hours (0.20 CEUs) on 1/2/2004



Temple University School of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Peter H. Doukas, Ph.D.
Dean, Temple University School of Pharmacy



Dear Participant:

Pharmacy Times and Temple University School of Pharmacy are pleased to forward your continuing education certificate of completion. Thank you for participating in this program.

We look forward to your continued interest in pharmacy education and hope we will have the opportunity of serving you again in the future.

Sincerely,

James R. Granato
Publisher, Pharmacy Times

Robert A Fecik
308 Harvard St. S.E., 8-101 WDH
Minneapolis, MN 55455



CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

This certifies that

Robert A. Fecik

has successfully completed the program

A Comparison of Product Development, Lifecycle, and Approval Pathways: Branded vs. Generic Products

ACPE Universal Program I.D. No. 057-999-02-020-H04

and earned 2.0 contact hours (0.20 CEUs) on 1/4/2004



Temple University School of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Peter H. Doukas, Ph.D.
Dean, Temple University School of Pharmacy

CONTINUING PHARMACEUTICAL EDUCATION STATEMENT OF CREDIT

DRUG STORE NEWS
CONTINUING EDUCATION PROGRAM
PO BOX 31180, TAMPA, FL 33631-3180



DRUG STORE NEWS is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

UNIVERSAL PROGRAM NUMBER

401-000-02-013-H04

Supported by: Eisai

LESSON NUMBER: 02-013
CREDIT HOURS: 2
DATE RECEIVED: 20040105

- 1. B 2. B 3. E 4. A 5. B
- 6. C 7. D 8. D 9. E 10. D
- 11. D 12. A 13. D 14. C 15. E
- 16. E 17. B 18. A 19. E 20. A

LESSON: Enhancing communication with today's aging population

ENROLLMENT# 5347758

Authorized
Signature:

A handwritten signature in cursive script, appearing to read 'Kimberly K. Werner', written over a horizontal line.

ROBERT FECIK
UNIVERSITY OF MINNESOTA
308 HARVARD ST. S.E.
8-101 WDH
MINNEAPOLISMN 55455

DATE: 01/05/2004

01052004143357